CBD and Alzheimer’s

Peer-reviewed studies into the potential effects of Cannabidiol and Alzheimer’s

On this page, CBD and Alzheimers, you will find research pertaining to the use of Cannabidiol and Cannabinoids and its possible effects on Alzheimer’s. The information below is not meant to influence your opinion, but rather give you access to a wealth of scientific literature in an attempt to make and educated and informed choice. Click Here to see all of the conditions that have been researched alongside CBD and Alzheimer’s.

Cannabinoids for the treatment of Agitation and Aggression in Alzheimer’s Disease. 

From the abstract:

Alzheimer’s disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness... findings from six studies showed significant benefits from synthetic cannabinoids—dronabinol or nabilone—on agitation and aggression… Given the relevance and findings to date, methodologically rigorous prospective clinical trials are recommended to determine the safety and efficacy of cannabinoids for the treatment of agitation and aggression in dementia and AD.

Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

From the abstract:

Oxidative stress with reactive oxygen species generation is a key weapon in the arsenal of the immune system for fighting invading pathogens and initiating tissue repair. If excessive or unresolved, however, immune-related oxidative stress can initiate further increasing levels of oxidative stress that cause organ damage and dysfunction…. growing evidence suggests that the endocannabnoid system, which includes the CB1 and CB2 G-protein-coupled receptors and their endogenous lipid ligands, may be an area that is ripe for therapeutic exploitation… cannabidiol, which may interact with the endocannabinoid system but has actions that are distinct offers promis as a prototype for anti-inflammatory drug development.

The therapeutic potential of the endocannabinoid system for Alzeimer’s disease.

From the abstract:

Based on the complex pathology of AD, a preventative, multimodal drug approach targeting a combination of pathological AD symptoms appears ideal. Importantly, cannabinoids show anti-inflammatory, neuroprotective and antioxidant properties and have immunosuppressive effects. Thus, the cannabinoid system should be a prime target for AD therapy… Furthermore, the phytocannabinoid cannabidiol is of particular interest as it lacks the psychoactive and cognition-impairing properties of other cannabinoids.

Endocannabinoid signalling in Alzheimer’s disease.  

From the abstract:

The present mini-review examines the evidence supporting the roles that ECs appear to play in Alzheimer’s disease and the potential for beneficial therapeutic manipulation of the EC signalling system. 

A Molecular Link Between the Active Component of Marijuana and Alzheimers Disease Pathology

From the abstract:

Compared to currently approved drugs prescribed for the treatment of Alzheimer’s disease, THC is a considerably superior inhibitor of Aβ aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.

Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells.

From the abstract:

Alzheimer’s disease is widely held to be associated with oxidative stress due, in part, to the membrane action of beta-amyloid peptide aggregates. Here, we studied the effect of cannabidiol… Our results indicate that cannabidiol exerts a combination of neuroprotective, anti-oxidative and anti-apoptotic effects against beta-amyloid peptide toxicity, and that inhibition of caspase 3 appearance from its inactive precursor, pro-caspase 3, by cannabidiol is involved in the signalling pathway for this neuroprotection.

The potential therapeutic effects of THC on Alzheimer’s disease.

From the abstract:

The purpose of this study was to investigate the potential therapeutic qualities of Δ9-tetrahydrocannabinol (THC) with respect to slowing or halting the hallmark characteristics of Alzheimer’s disease... These sets of data strongly suggest that THC could be a potential therapeutic treatment option for Alzheimer’s disease through multiple functions and pathways.

The role of endocannabinoid signaling in the molecular mechanism of neurodegeneration in Alzheimer’s disease.

From the abstract:

In this review, we recapitulate the role of endocannabinoid signaling in [Alzheimer’s disease] and the probable mechanisms through which modulators of the endocannabinoid system provide their effects, thus highlighting how this target might provide more advantages over other therapeutic targets.

Cannabinoids for the treatment of Agitation and Aggression in Alzheimer’s Disease. 

From the abstract:

Alzheimer’s disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness... findings from six studies showed significant benefits from synthetic cannabinoids—dronabinol or nabilone—on agitation and aggression… Given the relevance and findings to date, methodologically rigorous prospective clinical trials are recommended to determine the safety and efficacy of cannabinoids for the treatment of agitation and aggression in dementia and AD.

Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression.

From the abstract:

Pharmacological inhibition of beta-amyloid (Abeta) induced reactive gliosis may represent a novel rationale to develop drugs able to blunt neuronal damage and slow the course of Alzheimer’s disease (AD). Cannabidiol (CBD), the main non-psychotropic natural cannabinoid, exerts in vitro a combination of neuroprotective effects in different models of Abeta neurotoxicity. The present study, performed in a mouse model of AD-related neuroinflammation, was aimed at confirming in vivo the previously reported antiinflammatory properties of CBD… The results of the present study confirm in vivo anti-inflammatory actions of CBD, emphasizing the importance of this compound as a novel promising pharmacological tool capable of attenuating Abeta evoked neuroinflammatory responses.

Cannabidiol: a promising drug for neurodegenerative disorders?

From the abstract:

Neurodegenerative diseases represent, nowadays, one of the main causes of death in the industrialized country… In this contest, marijuana derivatives have attracted special interest, although these compounds have always raised several practical and ethical problems for their potential abuse. Nevertheless, among Cannabis compounds, cannabidiol (CBD), which lacks any unwanted psychotropic effect, may represent a very promising agent with the highest prospect for therapeutic use.

Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition.

From the abstract:

Alzheimer’s disease (AD) is characterized by amyloid-β deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition… the findings indicate that CB1 deficiency can worsen AD-related cognitive deficits and support a potential role of CB1 as a pharmacologic target.

The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses.

From the abstract:

…little is still known of the role of the endocannabinoid system in Alzheimer’sdisease (AD)… the available data indicate that endocannabinoids are likely to play in this disorder a role similar to that suggested in other neurodegenerative diseases, that is, to represent an endogenous adaptive response aimed at counteracting both the neurochemical and inflammatory consequences of beta-amyloid-induced tau protein hyperactivity, possibly the most important underlying cause of AD.

The role of phytochemicals in the treatment and prevention of dementia.

From the abstract:

Dementia pathologies such as Alzheimer’s disease (AD) are reaching epidemic proportions, yet they are not successfully managed by effective symptomatic treatments… phytochemicals discussed include cannabinoids (e.g. cannabidiol) from Cannabis sativa, which are emerging as potential therapeutic agents for [behavioural and psychological symptoms of dementia]… which have been investigated for their pharmacological activities relevant to dementia and their potential effects on delaying dementia progression.

Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARy.

From the abstract:

The amyloidogenic cascade is regarded as a key factor at the basis of Alzheimer’s disease (AD) pathogenesis… Cannabidiol (CBD), a Cannabis derivative devoid of psychotropic effects, has attracted much attention because it may beneficially interfere with several Aβ-triggered neurodegenerative pathways…

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic.

From the abstract:

The present paper summarizes the main experimental studies demonstrating the polyvalent properties of cannabinoid compounds for the treatment of AD, which together encourage progress toward a clinical trial…

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.

From the abstract:

Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD)… [Objective was] To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD)… Adding MCO to AD patients’ pharmacotherapy is safe and a promising treatment option.

Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview.

In particular, the attention of researchers has been focused on phytochemical compounds that have shown antioxidative, anti-amyloidogenic, anti-inflammatory and anti-apoptotic properties and that could represent important resources in the discovery of drug candidates against dementia. In this review, we summarize the neuroprotective effects of the main phytochemicals belonging to the polyphenol, isothiocyanate, alkaloid and cannabinoid families in the prevention and treatment of the most common kinds of dementia.

Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model.

Previous reports have demonstrated that the combination of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimer-like phenotype of AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Here, we provide evidence that such natural cannabinoids are still effective in reducing memory impairment…

Cannabidiol Modulates the Expression of Alzheier’s Disease-Related Genes in Mesenchymal Stem Cells

In conclusion, we have found that pre-treatment with CBD prevented the expression of proteins potentially involved in tau phosphorylation and Aβ production in [gingiva mesenchymal stem cells(GMSCs)]. Therefore, we suggested that GMSCs preconditioned with CBD possess a molecular profile that might be more beneficial for the treatment of [Alzheimer’s disease]. 

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease.

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties in vitro. Thus, it is investigated as a potential multifunctional treatment option for [Alzeimer’s disease(AD)]… The studies provide “proof of principle” that CBD and possibly CBD-THC combinations are valid candidates for novel AD therapies.

Neurological Aspects of Medical Use of Cannabidiol.

Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects... CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases… Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies.